Viromed Medical AG is reporting optimistic outcomes for its PulmoPlas remedy within the remedy of ventilator-associated pneumonia (VAP) in intensive care unit sufferers.
PulmoPlas is an investigational machine that makes use of chilly atmospheric plasma to focus on and destroy viruses and micro organism within the respiratory tract in 30-90 seconds, based on Viromed.
In keeping with the corporate, remedy with PulmoPlas destroys micro organism within the higher and decrease airways, together with the decrease alveoli, in 30-90 seconds (in MRSA micro organism). The process is characterised by a excessive diploma of tolerability, with none dangerous results on the respiratory epithelia (bronchial and alveolar), Viromed studies.
“The outcomes of our medical trial have far exceeded our expectations when it comes to efficacy and security. Primarily based on the out there information, we’re satisfied that PulmoPlas remedy will revolutionize pneumonia remedy worldwide,” mentioned Uwe Perbandt, CEO of Viromed Medical AG. “Our modern process has the potential to avoid wasting lives and considerably shorten hospital stays, and thus may benefit all hospitals with ICUs. As the one firm on the earth that may provide such a remedy, we’re conscious of our accountability and can work vigorously to make PulmoPlas out there to hospitals as shortly as attainable.”
The corporate says the examine outcomes are anticipated to be revealed in early summer time 2025, and the remedy shall be validated by way of a second process. Primarily based on the examine outcomes, Viromed plans to submit an software to the Federal Institute for Medicine and Medical Gadgets (BfArM) for advertising and marketing authorization of PulmoPlas as a medical machine for the remedy of VAP.
Extra data is accessible on the Viromed web site.
